BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
The Best 15 Applications for Efficiency and Association - 2Why Cannes Is the Ultimate New Year’s Eve Destination in the South of France’s Off-Season
- 3Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- 4Have gravitational waves provided the first hint of primordial black holes born during the Big Bang?
- 5Doctors say changes to US vaccine recommendations are confusing parents and could harm kids
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
- Most loved Occasion Dish: What Makes Your Merry Table?
- Vote In favor of Your Favored Menial helper Administration
- Polish law aimed at lowering petrol prices takes effect
- Vote In favor of Your Favored Kind Of Organic product
- Scientists discover black hole flare with the light of 10 trillion suns
- Cathay Pacific raises fuel surcharge on all flights by 34%
- Senegal president signs tough new anti-LGBT law doubling jail terms
- Novartis to build manufacturing hub in North Carolina, creating 700 jobs
